- Market Capitalization, $K 208,264
- Shares Outstanding, K 61,254
- Annual Sales, $ 3,600 K
- Annual Income, $ -74,160 K
- 60-Month Beta 1.57
- Price/Sales 59.29
- Price/Cash Flow N/A
- Price/Book 3.92
|Period||Period Low||Period High||Performance|
| || |
+0.25 (+7.99%)since 10/18/19
| || |
+0.51 (+17.59%)since 08/20/19
| || |
-0.38 (-10.03%)since 11/20/18
Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (Foamix or the Company), a specialty pharmaceutical company, today announced the completion of Phase 2 clinical trial enrollment of FCD105 for the treatment of...
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Foamix Pharmaceuticals,...
The following statement is being issued by Levi & Korsinsky, LLP:
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Foamix Pharmaceuticals Ltd. ("FOMX" or the "Company") (NASDAQ: FOMX) in connection...
Bragar Eagel & Squire, P.C., a nationally recognized stockholder law firm, has launched an investigation into whether the board members of Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) breached their fiduciary...
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Foamix (FOMX) delivered earnings and revenue surprises of -20.59% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
REHOVOT, Israel (AP) _ Foamix Pharmaceuticals Ltd. (FOMX) on Monday reported a loss of $23.2 million in its third quarter.
Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs...
Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,463,742,...